Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 45,984

Document Document Title
WO/2013/175053
Compounds of formula (I), wherein R1 is as defined in the claims, exhibit COMT enzyme inhibiting activity and are thus useful as COMT inhibitors.  
WO/2013/176567
The invention relates to the field of medicine and the pharmaceutical-chemical industry, and specifically to the field of neurology, and concerns new compositions containing memantine and melatonin. It has been established that a strengt...  
WO/2013/174133
Disclosed is an application of SBT in preventing and treating diabetes mellitus vasculopathy and neuropathy. The SBT can significantly increase the expression of p-insulin receptor β and the ratio of p-insulin receptor β to total insul...  
WO/2013/176503
The present invention relates to a neurodegenerative disease therapeutic agent, and, more specifically, provides a composition containing, as an active ingredient, an ALK (anaplastic lymphoma kinase) activity or expression inhibiting sub...  
WO/2013/177116
Provided herein is a method of treating neuromyelitis optica (NMO) in an animal or human subject comprising administering to the subject a composition comprising a therapeutically effective amount of an Fc region modified anli-AQP4 antib...  
WO/2013/175359
The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an ef...  
WO/2013/177224
The invention provides novel compounds having the general formula (I) and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as ...  
WO/2013/173941
Provided are a peptide comprising the amino acid sequence of DEAQETAVSSHEQD, the polynucleotide encoding it, the uses of said peptide for the treatment of the symptoms associated with pain and for the inhibition of the activity of influe...  
WO/2013/175215
Compounds of formula (I) are of use in the modulation of Kv3.1, Kv.3.2 and Kv3.3 channels and have utility in the treatment or prevention of related disorders.  
WO/2013/175508
The present invention provides stable pharmaceutical composition of Aripiprazole. In one embodiment, the present invention encompasses the use of crospovidone having peroxide content of less than 80 ppm, advantageously less than 50 ppm, ...  
WO/2013/177494
The present invention relates to a pharmaceutical composition for use in the treatment of cognitive symptoms of schizophrenia comprising administering a therapeutically effective amount of a selective agonist of neuronal nicotinic acetyl...  
WO/2013/176624
The present invention pertains to methods of treating stroke by administering anti-microRNA-320, optionally in conjunction with tissue plasminogen activator (tPA), as well as methods of reducing blood-brain barrier permeability by admini...  
WO/2013/177510
This application is directed to α-neuronal nicotinic receptor agonists selective for α7-subtype that are useful for improving cognition impairment in patients having schizophrenia, a schizophreniform disorder or a related schizophrenia...  
WO/2013/175376
The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount ...  
WO/2013/174882
The invention relates to a composition comprising NADH and D-galactose for treating a circadian rhythm disorder, in particular further comprising vitamins and/or coenzymes and/or minerals.  
WO/2013/177498
The present invention relates to pharmaceutical compositions for use in the treatment of cognitive symptoms of schizophrenia or a related schizophrenia spectrum psychotic disorder, comprising administering a therapeutically effective amo...  
WO/2013/177367  
WO/2013/175047
Use of a compound of formula (I) to manufacture a medicament for treating Gaucher's disease in a human subject, a pharmaceutical composition comprising a compound of formula (I), compounds of formula (Ib) and method for obtaining said co...  
WO/2013/177024
The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various di...  
WO/2013/177570
Provided herein are methods for treating a disease or condition of the central nervous system. The methods include administering to the subject having or at risk of having the disease or condition a composition comprising RLIP76. Also pr...  
WO/2013/175316
A method for treating Huntington's disease in a mammal in need thereof is disclosed. The method comprises administering to the mammal an effective amount of a compound of Structural Formula I, or a pharmaceutically acceptable salt thereo...  
WO/2013/177104  
WO/2013/174780
The present invention provides for compounds of Formula I and various embodiments thereof, and compositions comprising compounds of Formula I and various embodiments thereof. In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6, ...  
WO/2013/175315
The present invention generally concerns particular methods and compositions for treatment of a neurodegenerative disease, such as Alzheimer's Disease. In particular embodiments, there is a composition comprising Parthenolide and a secon...  
WO/2013/175205
NOVEL COMPOUNDS The invention relates to spiro derivatives, to the use of said derivatives intreating diseases and conditions mediated by modulation of voltage-gated sodium channels, to compositions containing said derivatives and proces...  
WO/2013/175211
The present invention relates to the prophylaxis of acute noise- induced hearing loss by administering a compound of formula (I): wherein: W is group (Wa), group (Wb) or group (Wc):  
WO/2013/175206
The invention relates to spiro derivatives, to the use of said derivatives in treating diseases and conditions mediated by modulation of voltage-gated sodium channels, to compositions containing said derivatives and processes for their p...  
WO/2013/176220
The present invention provides a circadian rhythm-regulating agent which comprises an inhibitor capable of inhibiting vasopressin receptors V1a and V1b as an active ingredient.  
WO/2013/174781
The present invention provides a compound of formula I having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the prese...  
WO/2013/177098
The present invention relates to a method of extracorporeally treating animal or human cerebrospinal fluid (CSF) for the extracorporeal removal of excitatory neurotransmitters (EN). Specifically, the invention pertains to a method for th...  
WO/2013/175415
The present invention relates to pyrimidine compounds, (the compounds of formula 1), in all its stereoisomeric and tautomeric forms and mixtures thereof in all ratios; and their pharmaceutically acceptable salts, solvates, prodrugs and p...  
WO/2013/177062
The present disclosure relates to compositions and methods for improving the safety of blood-brain barrier receptor-mediated blood- brain barrier transport.  
WO/2013/175469
The invention relates to a method for treating a neurodegenerative disorder and associated pathologies in a subject, specifically, Parkinson disease, using antagonist of ARTS protein. The invention further provides methods for the diagno...  
WO/2013/177484
[0119] The present invention provides methods of treating and pharmaceutical compositions useful for treating a mood disorder or depressive symptoms associated with pain, inducing analgesia and treating pain in a subject by administering...  
WO/2013/177565
In alternative embodiments, the invention provides formulations, pharmaceutical compositions, devices and other products of manufacture comprising a therapeutically effective mixture of an insulin and a pramlintide, and methods for makin...  
WO/2013/170969
The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-sp iro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and ...  
WO/2013/173730  
WO/2013/173707
Isolated metabolites of (1 R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]- methyl]propanamide, methods for their use, and compositions containing the metabolites.  
WO/2013/173608
Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of MECP2. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expr...  
WO/2013/172436
The invention pertains to glycosylated crocin compounds obtained by condensing glucose or glucose oligomer to one or more hydroxyl groups of crocin represented by formula (1) as novel glycosylated compounds of crocin, or a mixture thereo...  
WO/2013/170966
The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-sp iro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and ...  
WO/2013/170972
The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-sp iro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and ...  
WO/2013/173370
A method of treating a cellular injury in a subject comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of formula I: wherein at least one of R1 -R8 is a sulfonic acid, a carboxylic aci...  
WO/2013/171233
CacyBP/SIP interacts with several targets, including tubulin, and was shown to play a role in the organization of microtubules. To better understand the involvement of CacyBP/SIP in cytoskeletal physiology and pathophysiology, the neuron...  
WO/2013/170694
The present invention relates to a compound as represented by formula (I), pharmaceutical composition thereof as well as preparation method and uses thereof, in particular to the uses of the compound as represented by formula (I) for tre...  
WO/2013/170965
The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-sp iro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and ...  
WO/2013/173601
Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of BDNF. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expre...  
WO/2013/172087
[Problem] To provide a composition provided with nitric oxide production-inhibiting activity substantially free of cytotoxicity. [Solution] The present invention is characterized by comprising either dried fish meat of Dojo loach and of ...  
WO/2013/170385
It is described pharmaceutical compositions and methods for the treatment of viral infections, hypercholesterolemia, hypertriglyceridemia, Alzheimer's disease, prion disease and Duchene's muscular dystrophy with oligonucleotide chelate c...  
WO/2013/171345
The present invention relates to tri-substituted glycerol compounds according to formula (I) as described herein for use in the treatment of clinically isolated syndrome, relapsing remitting multiple sclerosis (RR-MS) and/or secondary pr...  

Matches 701 - 750 out of 45,984